GLP1R and lipodystrophy: In a similar manner, the increased insulin secretion in our liraglutide treated SKO mice indicate that GLP-1R agonists could drive greater endogenous insulin production in lipodystrophy patients and thereby reduce the requirements for high dose insulin injections that are often used by these individuals.